Three years of promise, proposals, and progress on optimizing the benefit/risk of medicines: a commentary on the 3rd FDA-DIA-PWG-PhRMA-BIO pharmacogenomics workshop

被引：9

作者：

Salerno, RA

Lesko, LJ

机构：

[1] Wyeth Ayerst Res, Worldwide Regulatory Affairs, Pharma & Translat Med, Collegeville, PA 19454 USA

[2] US FDA, Ctr Drug Evaluat & Res, Silver Spring, MD USA

来源：

PHARMACOGENOMICS JOURNAL | 2006年 / 6卷 / 02期

关键词：

D O I：

10.1038/sj.tpj.6500345

中图分类号：

Q3 [遗传学];

学科分类号：

071007 ; 090102 ;

摘要：

引用

页码：78 / 81

页数：4

共 5 条

[1]

*GUID IND, 2005, PHARM DAT SUBM

[2] Pharmacogenetics and pharmacogenomics in drug development and regulatory decision making: Report of the first FDA-PWG-PhRMA-DruSafe workshop [J].

Lesko, LJ ;

Salerno, RA ;

Spear, BB ;

Anderson, DC ;

Anderson, T ;

Brazell, C ;

Collins, J ;

Dorner, A ;

Essayan, D ;

Gomez-Mancilla, B ;

Hackett, J ;

Huang, SM ;

Ide, S ;

Killinger, J ;

Leighton, J ;

Mansfield, E ;

Meyer, R ;

Ryan, SG ;

Schmith, V ;

Shaw, P ;

Sistare, F ;

Watson, M ;

Worobec, A .

JOURNAL OF CLINICAL PHARMACOLOGY, 2003, 43 (04) :342-358

[3]

Salerno RA, 2004, PHARMACOGENOMICS, V5, P25

[4]

TREPICCHIO WL, 2005, IN PRESS PHARMACOGEN

[5]

WANG S, 2005, IN PRESS PHARMACOGEN

← 1 →